Medication-Induced Akathisia: Symptoms, Causes, Diagnosis, and Treatment

Medication-induced akathisia is a movement disorder characterized by a profoundly distressing subjective sense of inner restlessness and a compelling urge to move. The term comes from the Greek word akathízein, meaning "inability to sit." People experiencing akathisia often describe it not simply as fidgeting, but as an agonizing, almost unbearable need to be in motion — a sensation that can be difficult to articulate and is frequently misunderstood by clinicians and loved ones alike.

In the DSM-5-TR, akathisia is classified under Medication-Induced Movement Disorders and Other Adverse Effects of Medication (code G25.71). It is recognized as a clinically significant adverse effect most commonly associated with antipsychotic medications, though it can be caused by a range of other drugs as well.

Akathisia is one of the most common and most distressing side effects of antipsychotic treatment. Prevalence estimates vary depending on the medication and population studied, but research consistently indicates that 20% to 45% of patients taking first-generation (typical) antipsychotics experience some degree of akathisia. With second-generation (atypical) antipsychotics, rates are generally lower but still significant, with estimates ranging from 5% to 25%. When other causative medications — such as SSRIs, antiemetics, and calcium channel blockers — are included, the scope of affected individuals broadens considerably.

Despite its high prevalence, akathisia remains underdiagnosed and undertreated. The subjective nature of the distress, combined with its overlap with anxiety, agitation, and psychotic restlessness, means that clinicians may fail to recognize it or may mistakenly attribute the symptoms to the underlying psychiatric condition rather than to the medication itself. This misidentification can lead to dose increases of the offending agent — paradoxically worsening the very problem the patient is experiencing.

Akathisia has both subjective (internal experience) and objective (observable behavior) components. Both dimensions must be understood for accurate recognition.

Subjective Symptoms

• Intense inner restlessness: A feeling of being "driven" or unable to stay still, often described as tension, unease, or crawling sensations in the legs or throughout the body.
• Psychological distress: Marked anxiety, irritability, dysphoria, or a vague but overwhelming sense of discomfort. Many patients report that the sensation is one of the most intolerable experiences they have ever endured.
• Difficulty articulating the experience: Patients may struggle to describe exactly what they feel, sometimes saying things like "I can't relax," "I feel like I'm going to jump out of my skin," or "Something is terribly wrong but I can't explain it."

Objective (Observable) Signs

• Repetitive leg movements: Shifting weight from one foot to the other, crossing and uncrossing legs, or incessant rocking while seated.
• Pacing: Compulsive walking back and forth, often without purpose or destination.
• Inability to remain seated or still: Frequent standing, sitting, and standing again during conversations or activities.
• Marching or tramping in place: Rhythmic stepping movements while standing.
• Body rocking: Swaying the trunk forward and backward while sitting.

Warning Signs That Require Immediate Attention

Akathisia is not merely uncomfortable — it carries serious clinical consequences. Research has linked severe akathisia to:

• Suicidal ideation and behavior: The distress of akathisia has been associated with increased risk of suicidality, particularly in the early weeks of antipsychotic or antidepressant treatment.
• Aggression and impulsivity: The intense internal agitation can contribute to uncharacteristic aggression or impulsive actions.
• Treatment nonadherence: Akathisia is one of the leading causes of patients discontinuing antipsychotic medication on their own, which can destabilize the management of the underlying psychiatric condition.
• Worsening of psychiatric symptoms: The distress can exacerbate psychosis, mania, or depression, complicating the clinical picture.

Akathisia is primarily a drug-induced condition. Its underlying pathophysiology is not fully understood, but the leading hypothesis centers on dopamine receptor blockade, particularly of D2 receptors in the mesocortical pathway. This blockade is thought to create a functional imbalance between dopaminergic and other neurotransmitter systems — including serotonergic, noradrenergic, and GABAergic systems — leading to the characteristic restlessness.

Medications Most Commonly Associated With Akathisia

• First-generation (typical) antipsychotics: Haloperidol, chlorpromazine, fluphenazine, and perphenazine are among the most frequent offenders, with akathisia rates of 20–45%.
• Second-generation (atypical) antipsychotics: Aripiprazole (which has a unique partial agonist mechanism) is notably associated with akathisia. Risperidone, olanzapine, quetiapine, and ziprasidone can also cause it, though generally at lower rates.
• Selective serotonin reuptake inhibitors (SSRIs): Fluoxetine, sertraline, paroxetine, and other SSRIs can cause akathisia, sometimes within the first days to weeks of treatment. This is thought to be mediated through serotonergic modulation of dopamine pathways.
• Serotonin-norepinephrine reuptake inhibitors (SNRIs): Venlafaxine and duloxetine have been reported to cause akathisia.
• Antiemetics: Metoclopramide and prochlorperazine, which have dopamine-blocking properties, are well-known causes, particularly in emergency department and surgical settings.
• Other medications: Calcium channel blockers, lithium, buspirone, and certain anticonvulsants have also been implicated in case reports and smaller studies.

Risk Factors

• High medication dose: Akathisia is dose-dependent for many agents, with higher doses carrying greater risk.
• Rapid dose escalation: Starting at a high dose or increasing doses quickly increases susceptibility.
• High-potency antipsychotics: Agents with strong D2 affinity (e.g., haloperidol) are more likely to cause akathisia than lower-potency agents.
• Age: Middle-aged and older adults appear to be at higher risk for chronic forms of akathisia, while acute forms can affect patients of any age.
• Female sex: Some studies suggest a higher prevalence in women, though findings are mixed.
• Iron deficiency: Low serum ferritin levels have been associated with increased vulnerability to akathisia, likely because iron is a cofactor in dopamine synthesis.
• Comorbid mood disorders: Patients with depression or anxiety may be more susceptible to or more distressed by akathisia.
• History of akathisia: Previous episodes increase the likelihood of recurrence with re-exposure to causative agents.

Akathisia is classified by its temporal relationship to the offending medication. Understanding these subtypes is clinically important because they differ in prognosis and treatment response.

• Acute akathisia: Develops within days to weeks of starting or increasing a medication. This is the most common form and typically resolves with dose reduction or medication change. It is the type most frequently studied.
• Tardive akathisia: Emerges after prolonged treatment (usually months to years) with a dopamine-blocking agent. Unlike acute akathisia, tardive akathisia may persist or worsen even after the offending drug is discontinued. It shares pathophysiological features with tardive dyskinesia and can be more difficult to treat.
• Withdrawal akathisia: Occurs when an antipsychotic or other dopamine-blocking medication is reduced or discontinued. This form typically resolves within six weeks, though it can be intensely distressing during that period.
• Chronic akathisia: Akathisia that persists for more than three months. It may have begun as acute akathisia that was not adequately addressed, or it may represent tardive akathisia. Chronic forms are associated with greater functional impairment and psychological distress.

Some patients experience pseudoakathisia, in which the objective motor restlessness is present but the patient does not report the subjective feeling of inner discomfort. This is more common in elderly patients and in individuals with cognitive impairment, and it may represent a distinct neurological pattern.

There is no laboratory test or imaging study that definitively confirms akathisia. Diagnosis is clinical, based on a careful assessment of subjective complaints, observable motor behavior, and the temporal relationship to medication use.

Diagnostic Criteria (DSM-5-TR)

The DSM-5-TR identifies medication-induced acute akathisia (G25.71) and notes the following key features:

• Subjective complaints of restlessness, often in the legs, accompanied by observable movements such as fidgeting, rocking, pacing, or an inability to sit or stand still.
• Symptoms develop within a few weeks of starting or increasing a dopamine-blocking medication (or, less commonly, after reducing a medication used to treat extrapyramidal symptoms).
• The symptoms are not better explained by a mental disorder (e.g., psychotic agitation, anxiety disorder, substance withdrawal) or another neurological condition.

Rating Scales

The Barnes Akathisia Rating Scale (BARS) is the most widely used and validated instrument for assessing akathisia. It evaluates three components:

• Objective restlessness: Clinician observation of the patient's motor behavior during a seated examination.
• Subjective awareness of restlessness: The patient's own report of inner unease or compulsion to move.
• Subjective distress related to restlessness: How much suffering the akathisia causes.

A global clinical assessment score is then assigned, ranging from 0 (absent) to 5 (severe akathisia). The BARS is valuable not only for initial diagnosis but also for monitoring treatment response over time.

Differential Diagnosis

Accurate diagnosis requires distinguishing akathisia from several conditions that can present similarly:

• Anxiety and panic disorder: Generalized anxiety can produce restlessness, but it typically lacks the specific motor components of akathisia and the clear temporal relationship to medication changes.
• Psychotic agitation: Patients in an acute psychotic state may be restless and agitated, but their distress is usually related to psychotic content (delusions, hallucinations) rather than an isolated motor-subjective syndrome.
• Restless legs syndrome (RLS): RLS involves uncomfortable leg sensations and an urge to move, predominantly at rest and in the evening. Unlike akathisia, RLS typically follows a circadian pattern and is not linked to dopamine-blocking medications.
• Tardive dyskinesia: This involves involuntary, repetitive movements (often of the face and tongue) that are distinct from the purposeful, semi-voluntary movements of akathisia, though the two can co-occur.
• Substance withdrawal: Withdrawal from alcohol, benzodiazepines, or opioids can produce marked restlessness that may resemble akathisia.

The management of akathisia follows a stepwise approach, prioritizing identification of the causative medication and modification of the treatment regimen before adding new agents.

Step 1: Address the Offending Medication

• Dose reduction: If clinically feasible, reducing the dose of the causative drug is the first and most effective intervention. Even modest dose reductions can produce significant relief.
• Switching medications: If dose reduction is not sufficient or not possible, switching to an alternative medication with a lower propensity for akathisia is recommended. Among antipsychotics, quetiapine and clozapine are generally associated with the lowest risk.
• Discontinuation: When appropriate and safe, discontinuing the offending agent altogether resolves acute akathisia in most cases.

Step 2: Pharmacological Treatment of Akathisia

When the causative medication cannot be reduced or changed — for instance, when a specific antipsychotic is essential for managing an acute psychotic episode — adjunctive medications can be used to manage akathisia symptoms.

• Beta-adrenergic blockers: Propranolol (typically 30–80 mg/day) is the best-studied and most consistently effective pharmacological treatment for acute akathisia. Its mechanism in this context is not fully understood but is thought to involve central beta-adrenergic blockade. Other lipophilic beta-blockers such as metoprolol may also be effective.
• Benzodiazepines: Clonazepam (0.5–2 mg/day) and lorazepam have demonstrated efficacy, particularly when anxiety and distress are prominent features. However, the risk of dependence limits their use to short-term management.
• Anticholinergic agents: Benztropine and trihexyphenidyl are frequently used for extrapyramidal symptoms, but evidence for their effectiveness in akathisia specifically is weaker compared to their efficacy for dystonia and parkinsonism. They may be helpful when akathisia co-occurs with other extrapyramidal symptoms.
• Mirtazapine: This antidepressant with 5-HT2A receptor antagonist properties has shown promise in treating akathisia in several studies, typically at low doses (7.5–15 mg). Its serotonergic mechanism may help rebalance the dopamine-serotonin interaction disrupted by antipsychotics.
• Cyproheptadine: This antihistamine with serotonin-antagonist properties has been used in some cases, particularly for SSRI-induced akathisia, though evidence is limited to case reports and small studies.
• Vitamin B6 (pyridoxine): High-dose vitamin B6 (600 mg/day) has shown some benefit in a small number of studies, though the evidence base remains limited and the mechanism unclear.

Addressing Iron Deficiency

Because low iron stores have been associated with increased vulnerability to akathisia, checking serum ferritin levels is recommended. If ferritin is low (some clinicians use a threshold of less than 75 ng/mL for psychiatric populations), iron supplementation may improve symptoms.

Treatment of Tardive Akathisia

Tardive akathisia is more challenging to treat than the acute form. The same agents used for acute akathisia may be tried, but response rates are generally lower. Unlike acute akathisia, dose reduction of the offending drug may initially worsen tardive akathisia (similar to the phenomenon seen with tardive dyskinesia). Gradual, supervised tapering under specialist guidance is essential.

Acute akathisia generally carries a favorable prognosis when it is promptly recognized and managed. Dose reduction or medication switch resolves symptoms in the majority of cases, often within days to weeks. When pharmacological treatment with propranolol or benzodiazepines is required, most patients experience meaningful relief.

However, prognosis depends heavily on several factors:

• Speed of recognition: The sooner akathisia is identified and addressed, the better the outcome. Delayed recognition — especially when symptoms are misattributed to the underlying psychiatric condition — can lead to unnecessary dose increases, prolonged suffering, and progression to chronic or tardive forms.
• Type of akathisia: Acute akathisia typically resolves completely with appropriate management. Tardive akathisia is less predictable and may persist for months or years, even after the causative medication is discontinued. Chronic akathisia occupies a middle ground, with some patients achieving full resolution and others experiencing a prolonged course.
• Underlying condition: Patients whose psychiatric condition requires ongoing antipsychotic treatment face the challenge of balancing symptom control with side-effect management. This often requires ongoing collaboration between the patient and prescriber to find the optimal medication and dose.
• Patient awareness and advocacy: Patients who are educated about akathisia and feel empowered to report symptoms early tend to have better outcomes, as their concerns can be addressed before the condition becomes severe or entrenched.

It is important to acknowledge that for a subset of patients — particularly those with tardive or chronic akathisia — the condition can significantly impair quality of life, daily functioning, and adherence to necessary psychiatric treatment. These individuals benefit from specialized care and a compassionate, patient-centered approach.

Akathisia exists within a broader landscape of medication-induced movement disorders and conditions involving pathological restlessness. Understanding these related conditions aids in differential diagnosis and comprehensive care.

• Tardive dyskinesia: An involuntary movement disorder caused by prolonged use of dopamine-blocking agents, characterized by repetitive, purposeless movements — most often of the face, tongue, and jaw. It can co-occur with akathisia and shares a similar etiology involving dopaminergic dysfunction.
• Medication-induced parkinsonism: Characterized by tremor, rigidity, bradykinesia (slowed movement), and postural instability. Like akathisia, it is caused by dopamine blockade, but the motor presentation is distinct.
• Acute dystonia: Sustained, involuntary muscle contractions causing abnormal postures, often occurring early in antipsychotic treatment. This is another member of the extrapyramidal symptom family.
• Restless legs syndrome (RLS): A neurological condition involving uncomfortable sensations in the legs and an urge to move them, particularly at rest and in the evening. While phenomenologically similar to akathisia, RLS has a different etiology and is not typically medication-induced (though dopamine-blocking drugs can worsen it).
• Neuroleptic malignant syndrome (NMS): A rare but life-threatening reaction to dopamine-blocking agents characterized by fever, rigidity, autonomic instability, and altered consciousness. While distinctly more severe, NMS exists on the same spectrum of adverse drug reactions involving dopaminergic disruption.
• Serotonin syndrome: A potentially dangerous condition caused by excessive serotonergic activity, which can include agitation and restlessness among its features. It is important to distinguish this from SSRI-induced akathisia, as the management differs significantly.

If you or someone you know is experiencing symptoms that align with akathisia — particularly after starting, increasing, or changing a medication — it is important to seek professional evaluation promptly. Do not stop or change prescribed medications on your own, as abrupt discontinuation can cause withdrawal effects or destabilize the underlying condition being treated.

Seek Medical Attention If You Notice:

• A new or worsening sense of inner restlessness, agitation, or inability to sit still that coincides with a medication change
• An uncontrollable urge to pace, rock, fidget, or shift position, especially if it is distressing
• Marked irritability, anxiety, or emotional distress that emerged alongside physical restlessness
• Difficulty sleeping or maintaining focus due to persistent restlessness

Seek Urgent or Emergency Help If:

• You are experiencing thoughts of self-harm or suicide — akathisia-related suicidality is a recognized and serious risk
• The restlessness is so severe that it feels unbearable or is interfering with your ability to function safely
• You are experiencing signs of a more dangerous medication reaction, such as high fever, severe muscle rigidity, rapid heart rate, or confusion (which may indicate neuroleptic malignant syndrome)

When seeking help, clearly describe the timeline of your symptoms relative to medication changes. If possible, use specific language: telling a clinician "I feel an unbearable need to move that started after my medication was changed" communicates more diagnostic information than "I feel anxious." Bring a list of all current medications, including recent dose changes, to your appointment.

A psychiatrist or neurologist with experience in medication-induced movement disorders is ideally positioned to evaluate and manage akathisia. Your primary care provider can provide an initial assessment and referral if needed.

If you are in crisis, contact the 988 Suicide and Crisis Lifeline (call or text 988 in the United States) or go to your nearest emergency department.